



1/31/2007 04:34:27 AM

**ADZA FDA grants Adeza Biomedical's Gestiva orphan status**

Adeza announced that the Office of Orphan Products Development of the FDA has granted Orphan Drug designation covering Gestiva, the company's therapeutic candidate for the prevention of preterm birth in women with a history of preterm delivery. If Gestiva is approved, Orphan Drug designation provides the opportunity for seven years of U.S. market exclusivity.